PRESS RELEASE Alexandria, Va., Jan . 29, 2015 —The Academy of Managed Care Pharmacy applauds two crucial provisions in draft legislation issued this week by the home Energy and Commerce Committee that combat the abuse of controlled substances and payment fraud in the Medicare Part D prescription drug benefit program. AMCP CEO Edith A. Rosato, RPh, IOM issued the following declaration: The Academy is delighted the Committee’s expenses includes Sec.

AMAG’s partner, Takeda Pharmaceutical Organization, is responsible for all regulatory filings looking for the wide IDA indication for Feraheme in its licensed territories.. AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia AMAG Pharmaceuticals, Inc. Both studies have completed enrollment right now, with more than 1,400 individuals enrolled through 210 research sites globally. Allen, M.D., Ph.D., executive vice president and chief medical officer of AMAG. ‘As we complete data collection and evaluation over the next few months, the total results of the studies will form the basis for global regulatory submissions, that will seek to expand the indication of Feraheme for the treating IDA beyond the current indication for adult individuals with persistent kidney disease.’ AMAG plans to send a sNDA for the broader U.S.